Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

126
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
126
Global Regulatory Systems01:28

Global Regulatory Systems

371
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
371
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

373
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
373
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

94
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
94
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

277
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
277
Drug Regulation01:25

Drug Regulation

2.5K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fundamental changes in regulation to improve access to biosimilars.

Bulletin of the World Health Organization·2026
Same author

Vaccine Ligand Binding Assay Life Cycle Management, Assay Maintenance, Monitoring and Transfer.

Bioanalysis·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates (<u>PART 1A</u> - Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing & Reporting <u>PART 1B</u> - Regulatory Agencies' Input on Regulated Bioanalysis/BMV).

Bioanalysis·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV)).

Bioanalysis·2026
Same author

Data profile: cancer sample cohorts (stomach, breast, colorectal, and liver) in Korea.

Epidemiology and health·2025
Same author

Conference report WHO informal consultation on the draft WHO Guideline on the phasing out of animal tests for the quality control of biological products.

Biologicals : journal of the International Association of Biological Standardization·2025

Related Experiment Video

Updated: Nov 29, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K

Regulatory challenges with biosimilars: an update from 20 countries.

Hye-Na Kang1, Robin Thorpe2, Ivana Knezevic1

  • 1Department of Health Product Policy and Standards, World Health Organization, Geneva, Switzerland.

Annals of the New York Academy of Sciences
|November 22, 2020
PubMed
Summary

The World Health Organization (WHO) identified challenges in biosimilar regulation, including product availability and quality. Solutions involve information exchange, reliance pathways, reassessment of older products, and robust pharmacovigilance for biosimilar safety and interchangeability.

Keywords:
WHObiosimilarchallengesregulationsurvey

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.3K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.0K

Related Experiment Videos

Last Updated: Nov 29, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.3K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.0K

Area of Science:

  • Pharmaceutical Sciences
  • Regulatory Science
  • Public Health

Background:

  • The World Health Organization (WHO) developed guidelines for biosimilar evaluation in 2009.
  • Member states have faced challenges implementing these guidelines into regulatory practices.
  • A 2019-2020 WHO survey highlighted persistent issues in biosimilar regulation.

Purpose of the Study:

  • To identify remaining challenges in the regulatory evaluation of biosimilars.
  • To propose opportunities and solutions for regulatory authorities to address these challenges.
  • To enhance the global implementation of effective biosimilar regulatory frameworks.

Main Methods:

  • Analysis of a 2019-2020 World Health Organization (WHO) survey on biosimilar regulatory practices.
  • Identification of key challenges reported by member states.
  • Synthesis of proposed solutions and opportunities for regulatory authorities.

Main Results:

  • Four primary challenges were identified: unavailable reference products, resource limitations, variable product quality, and difficulties with interchangeability and naming.
  • Proposed solutions include international information exchange, acceptance of foreign reference products, and reliance/joint review pathways.
  • Recommendations also cover reassessment of pre-framework approved products and enhanced pharmacovigilance for safety and interchangeability.

Conclusions:

  • Addressing challenges in biosimilar regulation requires international collaboration and adaptive regulatory strategies.
  • Implementing proposed solutions can improve access to and confidence in biosimilar medicines.
  • Robust regulatory oversight, including pharmacovigilance, is crucial for ensuring the safety and efficacy of biosimilars.